What did Evercore change in the ABBV analyst rating on Feb 04, 2026?

Evercore ISI on Feb 04, 2026 maintained an **Outperform** rating for AbbVie (ABBV) and lowered its price target to **$228** from **$232**, reflecting modest adjustments to forecast assumptions.

Does a maintained Outperform mean AbbVie is a buy?

A maintained Outperform signals the analyst expects the stock to beat peers, but it is not a guaranteed buy signal. Investors should compare the ABBV analyst rating with other firms and check fundamentals before acting.

How significant is the price target cut to $228 for ABBV?

The $4 cut is modest and indicates fine‑tuning rather than a change in conviction. It matters for short‑term sentiment but has limited impact on long‑term valuation without further negative data.

Where can I see the Evercore note and more ABBV coverage?

The Evercore note is summarized in TheFly report; read it here [source](https://thefly.com/permalinks/entry.php/id4285107/4961286394/ABBV-AbbVie-price-target-lowered-by--at-Evercore-ISI-heres-why). For live model updates use the Meyka ABBV page [Meyka ABBV page](https://meyka.ai/stocks/ABBV).

Analyst Ratings

ABBV AbbVie Inc. Feb 2026 Evercore Maintains Outperform, PT lowered to $228

ByHuzaifa Zahoor February 5, 2026

Evercore ISI on February 04, 2026 maintained an Outperform rating on AbbVie Inc. (ABBV) while trimming its price target to $228 from $232. This ABBV analyst rating note keeps a positive stance despite the modest cut, signaling confidence in core franchises even as model inputs shift. The action came at 02:35 PM and coincided with a -0.72% move in the stock, equal to $-1.58 on the day. We flag market cap at $383,468,438,600 for scale and note how small target moves can still matter to portfolio positioning.